CJC-1295 with DAC 5mg

CJC-1295 with DAC is a tetra-substituted growth hormone-releasing hormone (GHRH) analog covalently bonded to a Drug Affinity Complex (DAC) moiety that binds reversibly to circulating serum albumin. The conjugation extends the functional half-life to approximately eight days, producing sustained elevations of GH and IGF-1 in published animal models. The 5mg presentation supports extended-release growth axis and somatotropic pathway investigation.

Supplied as a lyophilised peptide vial, supplied for reconstitution with bacteriostatic water. The 5mg size suits sustained-release studies, weekly-dose pharmacokinetic characterisation and protocols where infrequent administration is methodologically preferable.

Research Applications • Long-duration GH and IGF-1 secretion profile studies • Albumin-binding pharmacokinetic and half-life extension research • Somatotropic axis modulation in preclinical animal models • Sustained-release peptide delivery and bioconjugation characterisation

Specification • Identity: CJC-1295 with DAC (CAS 863288-34-0) • Molecular weight: 3367.94 g/mol • Purity: 99%+ verified by HPLC and Mass Spectrometry • Format: lyophilised peptide vial — reconstitute with bacteriostatic water before use • Storage: store lyophilised at -20°C; once reconstituted, refrigerate at 2-8°C and use within 4-6 weeks; protect from light

For research use only — not for human consumption.